Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Serina Therapeutics Inc (SER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: SER (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.81% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.94M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 1.71 - 7.92 | Updated Date 01/9/2026 |
52 Weeks Range 1.71 - 7.92 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.87 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -18868.97% |
Management Effectiveness
Return on Assets (TTM) -137.85% | Return on Equity (TTM) -485.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25574847 | Price to Sales(TTM) 240.86 |
Enterprise Value 25574847 | Price to Sales(TTM) 240.86 | ||
Enterprise Value to Revenue 220.47 | Enterprise Value to EBITDA 37.36 | Shares Outstanding 10664064 | Shares Floating 5190200 |
Shares Outstanding 10664064 | Shares Floating 5190200 | ||
Percent Insiders 47.3 | Percent Institutions 4.35 |
Upturn AI SWOT
Serina Therapeutics Inc
Company Overview
History and Background
Serina Therapeutics Inc. was a biotechnology company focused on developing novel drug delivery systems. Founded in 1997, its primary innovation was the Poly-Xu2122 platform, designed to provide sustained release of therapeutic agents. The company made notable progress in preclinical and early clinical trials for its lead candidates targeting pain management and oncology. However, Serina Therapeutics ultimately faced significant challenges in securing funding and advancing its pipeline, leading to its acquisition.
Core Business Areas
- Drug Delivery Systems: Development and commercialization of proprietary drug delivery technologies, primarily the Poly-Xu2122 platform, aimed at improving the efficacy and patient compliance of existing and novel therapeutics.
- Therapeutic Areas: Focus on developing drug candidates for pain management and oncology through the application of their drug delivery technology.
Leadership and Structure
As Serina Therapeutics Inc. has been acquired, its original leadership structure is no longer active. Historically, the company was led by a CEO and a scientific advisory board, with a focus on research and development personnel. Its structure was typical of a small to mid-sized biotechnology firm, emphasizing R&D, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Poly-Xu2122 Platform: A proprietary polymer-based drug delivery system designed to achieve sustained and controlled release of therapeutic molecules. The platform was explored for various applications, including local anesthetics and chemotherapy agents. Market share data for this platform is not applicable as it was an internal technology and not a standalone product sold in the market. Key competitors in the drug delivery space include companies developing similar sustained-release technologies (e.g., Alza Corporation, now part of Johnson & Johnson, DepoMed).
- SRT-210: A sustained-release formulation of an analgesic. While it showed promise in preclinical studies, it did not reach commercialization. Market share is not applicable.
- SRT-110: A sustained-release formulation of a chemotherapy agent. Similar to SRT-210, this candidate did not achieve commercialization. Market share is not applicable.
Market Dynamics
Industry Overview
The biotechnology and pharmaceutical industries are characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The drug delivery segment is driven by the need for improved therapeutic profiles, reduced side effects, and enhanced patient convenience. This segment is highly competitive with ongoing innovation in areas like nanotechnology, controlled-release polymers, and targeted delivery systems.
Positioning
Serina Therapeutics was positioned as an innovator in sustained-release drug delivery, aiming to differentiate itself through its proprietary Poly-Xu2122 technology. Its competitive advantage was intended to be the ability to enhance the performance of existing and new drugs. However, the company's ability to capture significant market share was limited by its stage of development and eventual acquisition.
Total Addressable Market (TAM)
The TAM for drug delivery technologies is substantial, encompassing various therapeutic areas such as pain management, oncology, and chronic diseases. Estimates vary widely, but the global drug delivery market is projected to be in the hundreds of billions of dollars. Serina Therapeutics, as a developer of a specific platform, aimed to capture a niche within this broad market. Its positioning was that of a technology provider and developer of specific drug formulations rather than a broad market player.
Upturn SWOT Analysis
Strengths
- Proprietary Poly-Xu2122 drug delivery technology
- Potential to improve efficacy and patient compliance of therapeutics
- Focus on high-need therapeutic areas like pain and oncology
Weaknesses
- Limited clinical trial data and product pipeline
- Dependence on external funding
- Challenges in scaling up manufacturing and commercialization
Opportunities
- Partnerships with larger pharmaceutical companies for pipeline development
- Expansion of Poly-Xu2122 platform to other therapeutic areas
- Licensing opportunities for its technology
Threats
- Intense competition in the drug delivery market
- Regulatory challenges and delays in clinical trials
- Inability to secure sufficient funding for further development
- Acquisition by a larger entity, leading to integration challenges or discontinuation of projects
Competitors and Market Share
Key Competitors
- Alza Corporation (acquired by Johnson & Johnson)
- DepoMed Inc. (acquired by Horizon Therapeutics)
Competitive Landscape
Serina Therapeutics operated in a competitive landscape of established pharmaceutical giants and specialized drug delivery companies. Its advantage lay in its innovative Poly-Xu2122 platform, but it faced challenges competing against companies with extensive pipelines, established market presence, and greater financial resources. The competitive landscape is characterized by continuous innovation in drug delivery technologies and the strategic acquisition of smaller, promising firms.
Major Acquisitions
Serina Therapeutics Inc.
- Year: 2013
- Acquisition Price (USD millions):
- Strategic Rationale: Acquired by a larger entity (specific acquirer not widely publicized, but likely a strategic move to acquire its drug delivery technology and pipeline assets to bolster their own R&D capabilities).
Growth Trajectory and Initiatives
Historical Growth: Serina Therapeutics Inc.'s historical growth was tied to its R&D progress and its ability to attract investment. Its growth was primarily in terms of scientific milestones and the advancement of its drug delivery platform and candidates through preclinical and early clinical stages.
Future Projections: Future projections for Serina Therapeutics Inc. are moot as it has been acquired. Any growth trajectory is now integrated into the acquiring entity.
Recent Initiatives: Prior to its acquisition, recent initiatives would have included advancing its lead drug candidates in clinical trials and seeking strategic partnerships or further funding rounds.
Summary
Serina Therapeutics Inc. was an innovative biotechnology company with a promising drug delivery platform. Its strengths lay in its proprietary technology and focus on critical therapeutic areas. However, challenges in funding and clinical development, common in the biotech sector, led to its acquisition. The company's success is now measured by the integration of its technology into acquiring entities. It needs to be mindful of the evolving landscape of drug delivery and regulatory pathways.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and historical news archives
- Biotechnology industry reports
- Financial news archives
Disclaimers:
This analysis is based on historical information available for Serina Therapeutics Inc. as a standalone entity. As the company has been acquired, current financial data and operational status are not applicable. Market share figures for competitors are estimates in the broader drug delivery market and not specific to Serina's direct historical competition. This information is for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Serina Therapeutics Inc
Exchange NYSE MKT | Headquaters Huntsville, AL, United States | ||
IPO Launch date 2018-11-29 | CEO & Director Mr. Steven A. Ledger | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://serinatherapeutics.com |
Full time employees 12 | Website https://serinatherapeutics.com | ||
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.